Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the ten brokerages that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, six have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $17.80.
A number of equities analysts have weighed in on EPRX shares. Stifel Nicolaus set a $25.00 price target on Eupraxia Pharmaceuticals in a research report on Thursday, September 24th. Oppenheimer started coverage on shares of Eupraxia Pharmaceuticals in a report on Thursday, June 25th. They issued an “outperform” rating and a $17.00 price objective on the stock. Wedbush initiated coverage on shares of Eupraxia Pharmaceuticals in a research report on Thursday, September 24th. They issued an “outperform” rating and a $17.00 price objective on the stock. HC Wainwright reissued a “buy” rating and issued a $11.00 price objective on shares of Eupraxia Pharmaceuticals in a research report on Thursday, October 1st. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a report on Thursday.
Get Our Latest Stock Analysis on Eupraxia Pharmaceuticals
Institutional Investors Weigh In On Eupraxia Pharmaceuticals
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. AXQ Capital LP boosted its stake in shares of Eupraxia Pharmaceuticals by 34.2% during the 2nd quarter. AXQ Capital LP now owns 21,150 shares of the company’s stock worth $140,000 after buying an additional 5,390 shares during the last quarter. Seven Fleet Capital Management LP acquired a new stake in shares of Eupraxia Pharmaceuticals in the second quarter valued at about $4,037,289. Bank of America Corp DE acquired a new stake in shares of Eupraxia Pharmaceuticals in the second quarter valued at about $1,750,000. Jupiter Topco LLC acquired a new stake in shares of Eupraxia Pharmaceuticals in the second quarter valued at about $6,851,000. Finally, Cibc World Market Inc. bought a new stake in Eupraxia Pharmaceuticals during the second quarter worth about $1,539,000.
Eupraxia Pharmaceuticals Stock Down 2.2%
EPRX stock opened at $6.62 on Friday. The company has a debt-to-equity ratio of 0.02, a current ratio of 16.00 and a quick ratio of 16.00. The stock has a market capitalization of $430.43 million, a P/E ratio of -6.49 and a beta of 0.83. Eupraxia Pharmaceuticals has a fifty-two week low of $5.25 and a fifty-two week high of $9.32. The business has a 50-day moving average of $7.53 and a 200-day moving average of $7.02.
Eupraxia Pharmaceuticals (NASDAQ:EPRX – Get Free Report) last announced its earnings results on Tuesday, August 11th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.02. On average, sell-side analysts anticipate that Eupraxia Pharmaceuticals will post -0.85 earnings per share for the current fiscal year.
About Eupraxia Pharmaceuticals
Eupraxia Pharmaceuticals Inc (NASDAQ:EPRX) is a Canadian clinical-stage biotechnology company focused on developing locally delivered therapies designed to treat disease at the site of action while potentially reducing systemic exposure and associated side effects. The company is headquartered in Victoria, British Columbia, and is developing candidates for inflammatory and other serious medical conditions.
Eupraxia’s lead program, EP-262, is an extended-release formulation of dexamethasone being developed for the treatment of pain and inflammation associated with osteoarthritis of the knee.
Featured Articles
- Five stocks we like better than Eupraxia Pharmaceuticals
- Bank of America Stock Sell-Off Looks Like a Buying Opportunity
- AST SpaceMobile Is Down 67%—Could SpaceX’s Mobile Push Deepen the Selloff?
- GlobalFoundries’ $21 Billion Deal Could Change the Economics of Chipmaking
- Fundamental and Technicals Signals Align for Costco: Is the Stock Finally Breaking Out?
Receive News & Ratings for Eupraxia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eupraxia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
